Successful treatment of osteosarcoma in a pregnant woman with survival of the gestational product: A case report and literature review
- Authors:
- Published online on: October 9, 2024 https://doi.org/10.3892/mi.2024.197
- Article Number: 73
-
Copyright : © Orpinel‑González et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Abstract
Introduction
Osteosarcoma (OS) is a highly prevalent malignant tumor of mesenchymal origin, accounting for 20% of all bone tumors (1). It occurs mainly in adolescents and the geriatric population (2). Etiologically, it is linked to genetic mutations on chromosome 6, previous exposure to radiotherapy, a high birth weight, repeated bone trauma and the African race (3). Mortality rates vary according to the histological grade, with ~3.1 deaths per million affected individuals annually (4). OS typically manifests in the long bones of the appendicular skeleton (5), primarily as localized lesions in the bone marrow; however, it can also occur in the periosteum, bone cortex and surrounding soft tissues (6). Histologically, it contains variable amounts of osteoid and fibrotic material, exhibiting different cellular predominance of osteoblasts, chondroblasts, or fibroblasts. It also exhibits various degrees of cellular degeneration and varying mitotic rates (7). Clinically, it presents with pain, swelling, limited joint mobility, and, in some cases, pathological fractures (8). Surgery combined with adjuvant chemotherapy is regarded as the optimal treatment for this neoplasm (9). Prompt intervention is crucial, as the tumor can metastasize to the lungs, requiring timely treatment to minimize mortality (10). Regrettably, diagnosis can be delayed in some patients as the symptoms may be mistaken for more common conditions, as observed when OS occurs during pregnancy. Currently, the treatment of OS during pregnancy may be controversial due to potential risks to the fetus (5).
Therefore, the present study describes the case of a pregnant woman diagnosed with OS in the appendicular skeleton during the first trimester. She underwent surgical treatment and adjuvant chemotherapy, exhibiting a positive response to treatment and successful survival of the gestational product.
Case report
The medical care for the patient discussed in the present case report was provided at Star Médica Hospital Chihuahua, Chihuahua, Mexico. The patient's care was administered from August, 2022 to January, 2023, in accordance with the standard protocols established by the institution and the specific pathology presented. As of the drafting of this clinical case report, both the mother and the infant are in good overall health.
A 21-year-old female with no notable medical history was in the first trimester of a physiological pregnancy, managed with mineral supplements and multivitamins. Around the 11th week of gestation, the patient reported swelling and localized pain in the distal third of her right tibia and fibula region (Fig. 1A). Anterior-posterior and lateral X-rays of the right ankle revealed granular lesions of variable radiographic density in the region of the right lateral malleolus (Fig. 2). Given the suspicion of malignancy, contrast-enhanced magnetic resonance imaging (MRI) of the abdominal-pelvic region, chest, and right ankle was conducted. The MRI revealed increased volume and signal intensity in the soft tissues surrounding the lateral malleolus. A non-mineralized bony matrix lesion was identified in the distal diaphysis of the fibula, appearing hypointense on the T1 sequence and hyperintense in the proximal diaphysis, with irregular margins measuring 66x30x20 mm. The lesion caused cortical destruction and extension into adjacent soft tissues. Post-contrast imaging revealed avid and heterogeneous enhancement of the affected region (Fig. 3).
Subsequently, following appropriate preparation, the patient underwent a biopsy of the affected area. The excised tissue was sent for analysis. The histopathology report described fragmented tissue measuring 6x4.2x1.2 cm in total, with a white or pink color, rough or granular texture, soft or semi-solid consistency, and exhibiting portions of white and hard bone. Microscopically, features consistent with a malignant mesenchymal neoplasm affecting bone, periosteum and adjacent fibroadipose tissue were observed. Abundant osteoid and fibrosis were present. Clusters or fascicles of spindle, oval, irregular, or polygonal cells with nuclear enlargement, oval, elongated, or irregular nuclei, vesicular or hyperchromatic, with one or two prominent nucleoli, two mitoses in 10 high-power fields, and scant cytoplasm were observed in the osteoid and fibrous stroma. Multinucleated giant tumor cells were also noted. The diagnosis of OS involving bone, periosteum and neighboring fibroadipose tissue, fragmented, measuring 6x4.2x1.2 cm, was established (Fig. 4). Upon the confirmation of diagnosis, the patient was closely monitored. At approximately the 15th week of gestation, she was admitted to the Department of Traumatology and Orthopedics of Hospital Star Médica Chihuahua (Chihuahua, Mexico) for the resection of the distal third of the right fibula. Following the surgical protocol, anesthesia was induced by regional blockade, and hemostatic control was established. The patient was positioned in dorsal decubitus, and asepsis and antisepsis techniques were employed for the lower right limb. Sterile fields were prepared, and an approach was made to the lateral malleolus. The skin, subcutaneous tissue and fascia were dissected, and the area between the long and short fibula and the distal third of the fibula was approached. A granular-looking tumor measuring ~8x5 cm was located and excised. Post-surgical cleansing and conventional wound closure were performed without complications (Fig. 1B). Following recovery, after 1 week of her admission the patient exhibited good progress and was admitted for a scheduled outpatient follow-up. Analgesic management and antibiotic therapy with clindamycin at 300 mg every 6 h for 7 days were prescribed, along with general care of the surgical site and follow-up at the outpatient clinic. The patient subsequently continued with an uncomplicated prenatal follow-up. Between 29 and 31 weeks of gestation, adjuvant chemotherapy was initiated with doxorubicin at 110 mg in 100 cc of 0.9% saline solution and cisplatin at 140 mg in 1,000 cc of 0.9% saline solution. Additionally, anti-emetic, anti-inflammatory and anti-edematous management was provided, along with the administration of 6 mg pegfilgrastim following chemotherapy to prevent neutropenia.
Following the completion of the chemotherapeutic regimen, the patient exhibited favorable progress and underwent a scheduled cesarean section at the beginning of the 37th week of gestation. The surgery was performed without complications, yielding a live product with a weight of 2,285 grams, a height of 48 cm, and Apgar scores of 9 at 1 and 5 min. At 1 week postpartum, the patient underwent three additional sessions of the same chemotherapeutic regimen. Subsequently, a biopsy was performed to evaluate the antitumor efficacy. A histopathological analysis revealed multiple bone fragments totaling 8x7 cm, characterized by a gray-brown, hard, irregular, opaque and trabecular appearance. The obtained sample was processed using 10% buffered formalin, then embedded in paraffin and sectioned into 50-µm-thick slices using a microtome. The sections were placed on slides and stained with hematoxylin and eosin; these procedures were performed in the Cytopathology and Oncological Pathology Laboratory, Histopath®, in accordance with standard guidelines. A microscopic examination revealed sections of cortical and medullary bone tissue with distinct intraparenchymal hemorrhage and diffuse fibrosis, alongside the loss of elements from all three hematopoietic series (myeloid, erythroid and platelets). Notably, no residual malignant neoplastic tissue was detected, indicating a complete pathological response (residual tumor, 0%) (Fig. 5).
A regards the follow-up of the gestational product, pediatric reports indicate a generally positive outcome, with only a few unrelated conditions. Notably, a cardiac murmur was diagnosed at 1 month of age, but was deemed benign. Upon the writing of the present manuscript, the patient has been asymptomatic for >1 year. Additionally, the infant experienced symptoms of gastroesophageal reflux, which led to nutritional issues, resulting in iron-deficiency anemia and proctocolitis with limited weight gain around the 5th month. All these conditions have been effectively treated. Currently, all symptoms have resolved, and there are no pathological findings linking the condition to in utero exposure to the antineoplastic drug or the maternal OS.
Discussion
The present study describes the case of a young pregnant woman diagnosed with OS in the distal fibula, who was successfully treated with surgery and adjuvant chemotherapy. It is important to highlight that the woman in the present case report had no evident risk factors for developing OS. Thus, this clearly demonstrates the unpredictable nature of this neoplasm in young individuals. Fortunately, long-term follow-up reports for this woman indicate that both she and the gestational product are in good health, with no pathologies linked to the primary tumor or arising from the treatment. Notably, the occurrence of neoplasms during pregnancy is rare, with an incidence of ~1 case per 1,000 pregnancies (11). A previous review suggested that the incidence of OS in pregnant women may be on the rise due to the increasing trend of delaying pregnancy until later ages (12). However, the age of the patient in the present study does not align with this trend. Therefore, it can be hypothesized that the patient in the present case report likely had more subtle risk factors that predisposed her to develop this neoplastic lesion, probably of a polygenic nature or related to specific age-related risk factors. As regards the latter, a previous retrospective study observed that the age group of 15 to 25 years was the one with the most significant increase in OS diagnoses over recent decades compared with other age groups (13). Additionally, previous reports have documented incidental diagnoses of OS in pregnant women and women on reproductive age while they were being treated for other conditions (14,15). In the patient described herein, the clinical manifestations observed were consistent with the typical presentations of OS in the appendicular skeleton (16). The initial evaluation of the edema and pain involved an ankle X-ray, which revealed radiodense and lytic lesions typical of this neoplasm (17). Although positron emission tomography is the ideal diagnostic tool for identifying metastases (18), herein, its use was restricted due to the pregnancy of the patient. Consequently, contrast-enhanced MRI was employed, as it effectively visualizes the extent of soft tissue involvement and the overall disease progression (17,19). In the absence of metastasis, surgical treatment combined with adjuvant chemotherapy was selected. Previous studies have demonstrated that this approach can preserve the affected limb and ensure a favorable long-term prognosis (9,20). Although surgery is a valid approach for treating localized stages of osteosarcoma, it can cause localized cellular stress, potentially leading to immune dysregulation and increasing the risk of tumor recurrence over time (21). Considering this and the young age of the patient in the present case report, the medical team decided on a combined treatment plan of surgery and adjuvant chemotherapy. Drug management during pregnancy has historically been contentious; advancements in pharmacokinetics and pharmacovigilance now support the safe use of medications during pregnancy for both the mother and fetus (22,23). In addition, recent advancements in therapies, particularly those utilizing nanoparticles, have demonstrated their effectiveness in the treatment of OS (24). However, the availability of antineoplastic drugs in the authors' hospital (Hospital Star Médica Chihuahua) is limited. Consequently, the selection of the medication was based on the established therapeutic efficacy of the drug for this type of cancer. Since the 1970s, the use of cisplatin has been shown to be associated with improved survival rates in OS by 90% and extended relapse-free periods by 60% (25). However, in the case described herein, cisplatin and doxorubicin were selected, as it remains effective at low doses for these lesions (26-28). The follow-up data confirmed a satisfactory antitumor response in the patient, along with the birth of the product without significant complications. As regards the treatment used, while the management of OS depends on the tumor stage, it is also closely aligned with the treatment protocols specific to each hospital (29). Cytotoxic therapies used in OS include alkylating agents (ifosfamide and cisplatin), antimetabolites (methotrexate and gemcitabine), topoisomerase inhibitors (etoposide), anthracyclines (doxorubicin), or microtubule inhibitors. Additionally, recent studies suggest that PD-1 inhibitors may serve as an effective adjuvant immunotherapy for patients with OS who have already undergone standard chemotherapy; this treatment has the potential to increase survival rates and lower the risk of long-term tumor recurrence (30,31). Other potential treatments include RNA silencers and certain nucleotide analogs, which have proven effective in other types of solid tumors. However, these are still in phase I and II clinical trials: (NCT02985125, https://clinicaltrials.gov/study/NCT02985125; and NCT02981342, https://clinicaltrials.gov/study/NCT02981342, respectively) and will require time before they become standard practice (32). In the authors' opinion, the treatment selected for the patient in the present case report was the most suitable, considering her personal circumstances and the available resources at the hospital.
The present study has a notable limitation which should be mentioned: The routine diagnosis of OS typically relies on the immunohistochemical analysis of the tumor tissue. Commonly used molecular markers include vimentin, S100 protein and CD99, which collectively assist in determining the cellular origin and genetic lineage of the tumor. However, due to resource limitations at Hospital Star Médica Chihuahua, the diagnosis of OS was based on clinical presentation and histopathological findings from the tumor sample. While this diagnostic approach is generally deemed sufficient (33), the absence of specific markers hampers a comprehensive characterization of the neoplasm. For purposes of comparison, a summary of previously reported similar cases reports in the medical literature is provided in Table I (11,34-48). Future research is thus required to explore the utility of these markers as part of a thorough diagnostic screening for similar lesions. However, given the positive response of the patient to chemotherapy and the outcomes reported during the resection, it is expected that she will sustain a favorable long-term prognosis.
Acknowledgements
Not applicable.
Funding
Funding: No funding was received.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
CAOG, JHL and CAMM participated in the diagnostic and therapeutic approach of the patient, as well as in supervising the writing of the manuscript. MIG, AART and RGRM participated in the surgical procedure, as well as in obtaining relevant medical imaging of the patient, including MRI studies, radiographs, and histopathology, also were responsible for the synthesis of the clinical information of this case, the bibliographic research and the redaction of the work. CAOG and JHL confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.
Ethics approval and consent to participate
The patient signed permission for her participation in the present case report.
Patient consent for publication
The patient voluntarily provided consent for the publication of the present case report and any personal images illustrating her condition. These images do not reveal sensitive information that could identify the patient.
Competing interests
The authors declare that they have no competing interests.
References
Zhao X, Wu Q, Gong X, Liu J and Ma Y: Osteosarcoma: A review of current and future therapeutic approaches. Biomed Eng Online. 20(24)2021.PubMed/NCBI View Article : Google Scholar | |
Jeong HI, Lee MJ, Nam W, Cha IH and Kim HJ: Osteosarcoma of the jaws in Koreans: Analysis of 26 cases. J Korean Assoc Oral Maxillofac Surg. 43:312–317. 2014.PubMed/NCBI View Article : Google Scholar | |
Mirabello L, Pfeiffer R, Murphy G, Daw NC, Patiño-García A, Troise RJ, Hoover RN, Douglass C, Schüz J, Craft WA and Savage SA: Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control. 22:899–908. 2011.PubMed/NCBI View Article : Google Scholar | |
Mirabello L, Troisi RJ and Savage AS: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009.PubMed/NCBI View Article : Google Scholar | |
Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014.PubMed/NCBI View Article : Google Scholar | |
Klein MJ and Siegal GP: Osteosarcoma: Anatomic and histologic variants. Am J Clin Pathol. 125:555–581. 2006.PubMed/NCBI View Article : Google Scholar | |
Enneking WF, Spanier SS and Goodman MA: Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg. 62:1027–1030. 1980.PubMed/NCBI | |
Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015.PubMed/NCBI View Article : Google Scholar | |
Anderson ME: Update on survival in osteosarcoma. Orthop Clin North Am. 47:283–292. 2016.PubMed/NCBI View Article : Google Scholar | |
PosthumaDeBoer J, Witlox MA, Kaspers GJL and van Royen BJ: Molecular alterations as target for therapy in metastatic osteosarcoma: A review of literature. Clin Exp Metastasis. 28:493–503. 2011.PubMed/NCBI View Article : Google Scholar | |
Figueiro-Filho EA, Al-Sum H, Parrish J, Wunder JS and Maxwell C: Maternal and fetal outcomes in pregnancies affected by bone and soft tissue tumors. AJP Rep. 8:e343–e348. 2018.PubMed/NCBI View Article : Google Scholar | |
Lee YY, Roberts CL, Dobbins T, Stavrou E, Black K, Morris J and Young J: Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: A population-based linkage study. BJOG. 119:1572–1582. 2012.PubMed/NCBI View Article : Google Scholar | |
Cole S, Gianferante DM, Zhu B and Mirabello L: Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017. Cancer. 128:2107–2118. 2022.PubMed/NCBI View Article : Google Scholar | |
Santos TA, Américo MG, Priante AVM, de Oliveira MF and Anbinder AL: Jaw osteosarcoma and pregnancy: A rare coexistence. Autops Case Rep. 12(e2021359)2022.PubMed/NCBI View Article : Google Scholar | |
Harrold E, McMahon E, McGing P and Higgins M: βhCG-secreting osteosarcoma. BMJ Case Rep. 2017(bcr2016218438)2017.PubMed/NCBI View Article : Google Scholar | |
Chen B, Zeng Y, Liu B, Lu G, Xiang Z, Chen J, Yu Y, Zuo Z, Lin Y and Ma J: Risk factors, prognostic factors, and nomograms for distant metastasis in patients with newly diagnosed osteosarcoma: A population-based study. Front Endocrinol (Lausanne). 12(672024)2021.PubMed/NCBI View Article : Google Scholar | |
Geller DS and Gorlick R: Osteosarcoma: A review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 8:705–718. 2010.PubMed/NCBI | |
Zhang X and Guan Z: PET/CT in the diagnosis and prognosis of osteosarcoma. Front Biosci (Landmark Ed). 23:2157–2165. 2018.PubMed/NCBI View Article : Google Scholar | |
Dönmez FY, Tüzün U, Başaran C, Tunaci M, Bilgiç B and Acunaş G: MRI fndings in parosteal osteosarcoma: Correlation with histopathology. Diagn Intervent Radiol. 14:142–152. 2008.PubMed/NCBI | |
Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B and Urban C: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 49:1221–1230. 1982.PubMed/NCBI View Article : Google Scholar | |
Stock SJ and Norman JE: Medicines in pregnancy. F1000Res 8: F1000 Faculty Rev-911, 2019. | |
Howlader N, Noone AM, Krapcho ME, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR and Chen HS: SEER cancer statistics review, 1975-2016. National Cancer Institute, Bethesda, MD, pp1423-1437, 2019. | |
Rothzerg E, Pfaff AL and Koks S: Innovative approaches for treatment of osteosarcoma. Exp Biol Med (Maywood). 247:310–316. 2022.PubMed/NCBI View Article : Google Scholar | |
Yuan P, Min Y and Zhao Z: Multifunctional nanoparticles for the treatment and diagnosis of osteosarcoma. Biomater Adv. 151(213466)2023.PubMed/NCBI View Article : Google Scholar | |
Ferrari S and Serra M: An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 16:2727–2736. 2015.PubMed/NCBI View Article : Google Scholar | |
Misaghi A, Goldin A, Awad M and Kulidjian AA: Osteosarcoma: A comprehensive review. SICOT J. 4(12)2018.PubMed/NCBI View Article : Google Scholar | |
Huang H, Quan Y, Qi X and Liu P: Neoadjuvant chemotherapy with paclitaxel plus cisplatin before radical surgery for locally advanced cervical cancer during pregnancy: A case series and literature review. Medicine (Baltimore). 100(e26845)2021.PubMed/NCBI View Article : Google Scholar | |
Barani M, Mukhtar M, Rahdar A, Sargazi S, Pandey S and Kang M: Recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma. Biosensors (Basel). 11(55)2021.PubMed/NCBI View Article : Google Scholar | |
Kim MS, Bolia IK, Iglesias B, Sharf T, Roberts SI, Kang H, Christ AB and Menendez LR: Timing of treatment in osteosarcoma: Challenges and perspectives-a scoping review. BMC Cancer. 22(970)2022.PubMed/NCBI View Article : Google Scholar | |
Lilienthal I and Herold N: Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: A review of current and future strategies. Int J Mol Sci. 21(6885)2020.PubMed/NCBI View Article : Google Scholar | |
Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH and Jones RL: Future directions in the treatment of osteosarcoma. Cells. 10(172)2021.PubMed/NCBI View Article : Google Scholar | |
Shoaib Z, Fan TM and Irudayaraj JMK: Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 179:201–217. 2022.PubMed/NCBI View Article : Google Scholar | |
Angiero F, Moltrasio F, Cattoretti G and Valente MG: Clinical and histopathological profile of primary or secondary osteosarcoma of the jaws. Anticancer Res. 31:4485–4489. 2011.PubMed/NCBI | |
Pratt CB, Rivera G and Shanks E: Osteosarcoma during pregnancy. Obstet Gynecol. 50 (1 Suppl):24s–26s. 1977.PubMed/NCBI | |
Haerr RW and Pratt AT: Multiagent chemotherapy for sarcoma diagnosed during pregnancy. Cancer. 56:1028–1033. 1985.PubMed/NCBI View Article : Google Scholar | |
Huvos AG, Butler A and Bretsky SS: Osteogenic sarcoma in pregnant women. Prognosis, therapeutic implications, and literature review. Cancer. 56:2326–2331. 1985.PubMed/NCBI View Article : Google Scholar | |
Adair A, Harris SA, Coppen MJ and Hurley PR: Extraskeletal Ewings sarcoma of the small bowel: Case report and literature review. J R Coll Surg Edinb. 46:372–374. 2001.PubMed/NCBI | |
Nakajima W, Ishida A, Takahashi M, Hirayama M, Washino N, Ogawa M, Takahashi S and Okada K: Good outcome for infant of mother treated with chemotherapy for ewing sarcoma at 25 to 30 weeks' gestation. J Pediatr Hematol Oncol. 26:308–311. 2004.PubMed/NCBI View Article : Google Scholar | |
Nepal P, Singh GK, Singh MP, Bajracharya S, Khanal GP and Pandey SR: Osteosarcoma in pregnancy. JNMA J Nepal Med Assoc. 44:100–101. 2005.PubMed/NCBI | |
Koçak H, Karapolat S, Gündogdu C, Bozkurt E and Unlü Y: Primary cardiac osteosarcoma in a pregnant woman. Heart Vessels. 21:56–58. 2006.PubMed/NCBI View Article : Google Scholar | |
Kanazawa I, Yamauchi M, Yano S, Imanishi Y, Kitazawa R, Nariai Y, Araki A, Kobayashi K, Inaba M, Maruyama R, et al: Osteosarcoma in a pregnant patient with McCune-Albright syndrome. Bone. 45:603–608. 2009.PubMed/NCBI View Article : Google Scholar | |
Han WY, Bi CJ, Zhao YY, Zhu X, Li M, Wang J and Guo XY: A case of anesthesia for caesarean section in a late pregnant woman with recurrent femoral osteosarcoma. Beijing Da Xue Xue Bao Yi Xue Ban. 43:908–910. 2011.PubMed/NCBI(In Chinese). | |
Gonin J, Larousserie F, Dousset B, Rousseau J, Delattre O, Waintrop C, Tsatsaris V, Pierga JY, Vacher-Lavenu MC and Tissier F: An unusual adrenal tumor: Ewing tumor. Ann Pathol. 31:28–31. 2011.PubMed/NCBI View Article : Google Scholar : (In French). | |
Corrêa RR, Espindula AP, Machado JR, Paschoini MC, Pacheco Olegário JG, Rocha LP and dos Reis MA: Osteosarcoma in a pregnant woman: Case report. Arch Gynecol Obstet. 286:1601–1602. 2012.PubMed/NCBI View Article : Google Scholar | |
Ding Y, Huang Z, Ding Y, Jia Z, Gu C, Xue R and Yang J: Primary ewing's sarcoma/primitive neuroectodermal tumor of kidney with caval involvement in a pregnant woman. Urol Int. 97:365–368. 2016.PubMed/NCBI View Article : Google Scholar | |
Narla SL, Stephen P, Kurian A and Annapurneswari S: Well-differentiated liposarcoma of the breast arising in a background of malignant phyllodes tumor in a pregnant woman: A rare case report and review of literature. Indian J Pathol Microbiol. 61:577–579. 2018.PubMed/NCBI View Article : Google Scholar | |
Breda JR, Aljure O, Sfakianaki AK and Loebe M: Cesarean section in patient with metastatic Ewing sarcoma requiring VA-ECMO support. J Card Surg. 36:4756–4758. 2021.PubMed/NCBI View Article : Google Scholar | |
Regmi A, Raouf M, Mudaliar KM, Speiser JJ and Ananthanarayanan V: Primary cutaneous ewing sarcoma of the scalp with metastasis to the lung: An unusual manifestation during pregnancy. Am J Dermatopathol. 45:127–132. 2023.PubMed/NCBI View Article : Google Scholar |